Humans have such a wide range of drug today for the treatment of anything from colds and flu to cancer. While preclinical studies may give some indication of the safety of drugs, it is no substitute for a real test on how the drug will interact with the human body.
At the beginning of the trial, the drug’s developer will determine what they want to achieve for each of the various stages or ‘research phase’ of the court. The purpose of this is to produce a developer of new drugs to the market with a solid, proven therapeutic benefit. The high number of drugs that never make it to market, with less than 10% of those entering clinical trials that once approved by the relevant regulatory bodies. For more information on Adaptive Phase 1 Clinical Studies, visit a site like Richmond Pharmacology, leaders in Adaptive Phase 1 Clinical Studies.
Temptation is just a fraction of what is involved in developing new drugs. Life-saving Drugs future must first be found, made, purified, clarified and tested in laboratory conditions before it ever reaches the stage of human testing. This is where many compounds fail and never reached the phase of human testing.
Pre-clinical studies include monitoring the effects of drugs on cells. It is a long process, difficult and slow and can take between 10 to 13 years of laboratory regulations. During the pre-clinical phase, it is important to determine the safest dose for a first introduction to human testing. This is true, not only for drugs but also devices, diagnostic tools and gene therapy solutions.